Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
NCT07599345 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 23955
Last updated 2026-05-20
Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Heart Failure With Reduced Ejection Fraction
- Chronic Heart Failure
Interventions
- DRUG
-
Sitagliptin
Initiation of sitagliptin described in electronic health records is used as the reference.
- DRUG
-
Empagliflozin
Initiation of empagliflozin described in electronic health records is used as the exposure.
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-13
- Primary Completion
- 2026-06-01
- Completion
- 2026-06-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure
NCT05734690 ·Status: COMPLETED ·Phase: PHASE4
-
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
NCT03271879 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
NCT03332212 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
NCT03198585 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
NCT04157751 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
NCT07038356 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
NCT04049045 ·Status: COMPLETED ·Phase: PHASE2
-
Use of SGLT2i in noHCM With HFpEF
NCT06401343 ·Status: RECRUITING ·Phase: PHASE4
-
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
NCT03448419 ·Status: COMPLETED ·Phase: PHASE3
-
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
NCT03448406 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
NCT03030222 ·Status: COMPLETED ·Phase: PHASE4
-
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
NCT04509674 ·Status: COMPLETED ·Phase: PHASE3
-
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
NCT06632561 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Acute and Chronic Empagliflozin Heart Failure
NCT05553938 ·Status: RECRUITING ·Phase: PHASE1
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
NCT06507657 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
NCT06046612 ·Status: UNKNOWN ·Phase: PHASE4
-
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT05084235 ·Status: COMPLETED ·Phase: PHASE2
-
EMPagliflozin After Aortic Valve Replacement
NCT06171802 ·Status: COMPLETED ·Phase: PHASE4
-
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
NCT05129722 ·Status: TERMINATED ·Phase: PHASE4
-
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
NCT03485222 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
NCT03292653 ·Status: TERMINATED ·Phase: PHASE2
-
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
NCT03066804 ·Status: COMPLETED ·Phase: PHASE3
-
The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
NCT05042973 ·Status: COMPLETED ·Phase: PHASE2
-
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
NCT03591991 ·Status: UNKNOWN ·Phase: NA
-
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
NCT03128528 ·Status: COMPLETED ·Phase: PHASE2